Electronic Resource
Springer
Cancer chemotherapy and pharmacology
3 (1979), S. 49-55
ISSN:
1432-0843
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary Thirty patients with disseminated malignant tumors received 0.5–2 mg vincristine/m2 as a continuous infusion for 1–5 days. Tumor regressions were observed in five patients (17%) who had all received polychemotherapy before. Side effects occurred in 22 patients (73%). Toxicity was mainly neurological in type, and reversible. Eleven patients (37%) suffered from deep nagging pain. Six patients (20%) had paralytic ileus; caerulein, a decapeptide, was given to two of them and led to a prompt resolution of the symptoms. Monitoring of immune parameters in ten patients revealed a transient depression of T and B cell function. Vincristine is highly toxic when given as continuous infusion in doses of 1.2 mg/m2 or more daily. Therefore this modality is not recommended for routine clinical use. Future studies of continuous vincristine infusions should use less than 1.2 mg vincristine/m2 daily.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00254420
| Library |
Location |
Call Number |
Volume/Issue/Year |
Availability |
